When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia.
Publication
, Journal Article
Reed, SD
Published in: Value Health
December 2011
Duke Scholars
Published In
Value Health
DOI
EISSN
1524-4733
Publication Date
December 2011
Volume
14
Issue
8
Start / End Page
1055 / 1056
Location
United States
Related Subject Headings
- Thiazoles
- Pyrimidines
- Piperazines
- Leukemia, Myeloid, Chronic-Phase
- Imatinib Mesylate
- Humans
- Health Policy & Services
- Dasatinib
- Benzamides
- 4407 Policy and administration
Citation
APA
Chicago
ICMJE
MLA
NLM
Reed, S. D. (2011). When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia. Value Health, 14(8), 1055–1056. https://doi.org/10.1016/j.jval.2011.10.001
Reed, Shelby D. “When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia.” Value Health 14, no. 8 (December 2011): 1055–56. https://doi.org/10.1016/j.jval.2011.10.001.
Reed SD. When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia. Value Health. 2011 Dec;14(8):1055–6.
Reed, Shelby D. “When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia.” Value Health, vol. 14, no. 8, Dec. 2011, pp. 1055–56. Pubmed, doi:10.1016/j.jval.2011.10.001.
Reed SD. When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia. Value Health. 2011 Dec;14(8):1055–1056.
Published In
Value Health
DOI
EISSN
1524-4733
Publication Date
December 2011
Volume
14
Issue
8
Start / End Page
1055 / 1056
Location
United States
Related Subject Headings
- Thiazoles
- Pyrimidines
- Piperazines
- Leukemia, Myeloid, Chronic-Phase
- Imatinib Mesylate
- Humans
- Health Policy & Services
- Dasatinib
- Benzamides
- 4407 Policy and administration